Duration of Antibiotic Therapy in Acute Kidney Graft Pyelonephritis (AGPN): Effect on the Risk of Recurrence

Active, not recruiting

• Conditions: Pyelonephritis Acute; Kidney Transplantation Recipients

• Registration Number: NCT06848816
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The aim of this study is to evaluate the impact of the duration of antibiotic therapy on the risk of recurrence in kidney graft pyelonephritis. The secondary objectives are to identify the factors associated with the duration of antibiotic therapy in acute kidney graft pyelonephritis, identify the factors associated with recurrence of acute kidney graft pyelonephritis within 3 months, evaluate the impact of the duration of antibiotic therapy on antibiotic-related complications and assess the impact of the duration of antibiotic therapy on the progression of renal function after acute kidney graft pyelonephritis.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-01-01
• Status Verified: 2025-02
• Study First Submitted: 2025-02-16
• Study First Submitted QC: 2025-02-21
• Last Update Submitted: 2025-02-21
• Study First Posted: 2025-02-27
• Last Update Posted: 2025-02-27
• Primary Completion: 2025-04-30
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Adult patients
• Kidney transplant recipients with a functional graft.
• Hospitalization with acute pyelonephritis (APN) defined by fever OR chills (noted in the clinical records) AND bacteriuria AND exclusion of another obvious cause of fever. (For rehospitalizations, also include cases where antibiotic therapy was initiated based on suspicion, even in the absence of documented infection.)

Exclusion Criteria

• Age < 18 years.
• Vacationing patient or lost to follow-up with follow-up < 3 months.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Relaspe AGPN	3 month	Rehospitalization for acute kidney graft pyelonephritis (AGPN) within three months after completion of treatment

Secondary Outcome Measures

Name	Time	Method
Early AGPN relapse	1 month	Rehospitalization for acute kidney graft pyelonephritis (AGPN) within one month after completion of treatment
ITU relapse	3 month	Antibiotic treatment for urinary tract infection within 3 months after completion of treatment.
Identical microorganism relapsing AGPN	3 month	New episode of AGPN with the same pathogen within 3 months after completion of treatment
Multidrug resistant emerging pathogens	3 month	Infection with a multidrug-resistant bacteria within 3 months after completion of treatment
Clostridioides difficile colitis	3 month	Occurrence of Clostridioides difficile colitis within 3 months after completion of treatment
Early kidney function evolution	1 month	Evolution of renal function (creatininemia) 1 month after completion of treatment for APNAG.
3 month kidney function evolution	3 month and 21 days	Evolution of renal function (creatininemia) 3 +/- 21 days after completion of treatment for AGPN
Risk factors	3 month	Clinical and biological Factors associated with AGPN recurrence independently of the duration of antibiotic therapy

Trial Locations

Locations (1)

CHU de Nancy; 🇫🇷 Nancy, France